ReviewCureus2023
Metabolic Syndrome Causing Cognitive Impairment in Patients With Schizophrenia: A Systematic Review.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- The psychoneuroimmuneendocrine system, epigenetics, and the integration of morphogenetic fields: a systematic review of their role in unconscious ontogenesis.Frontiers in systems neuroscience · 2026Pooled it
- Schizophrenia and dementia across the lifespan: epidemiological links, cognitive trajectories, and the pathophysiological interplay.Frontiers in neurology · 2026Review
- Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).Molecular medicine reports · 2025Review
- Factors associated with cognitive impairment for people with mental health disorders: screening from general hospitals and an emergency care unit in Brazil.BMC psychiatry · 2025Article
- Investigating the association of the plasma lipidomic profile with cognitive performance and genetic risk in the PsyCourse study.Translational psychiatry · 2025Article
- The role of cognitive function in predicting metabolic risk in schizophrenia: a multi-model comparison incorporating clinical features.Frontiers in psychiatry · 2025Article
- Knowledge, Attitude, and Practice of Medical Staff Towards Metabolic Syndrome in Schizophrenia in Chinese Hospitals: A Cross-Sectional Study.Journal of multidisciplinary healthcare · 2025Article
- Research on the influencing factors of the development of metabolic syndrome in patients with schizophrenia and the intervention effect of dance movement therapy.Frontiers in psychiatry · 2025Article
- Managing health in dual diagnosis: narratives from individuals with schizophrenia and diabetes.Frontiers in psychiatry · 2025Article
- Intestinal permeability biomarkers in patients with schizophrenia: Additional support for the impact of lifestyle habits.European psychiatry : the journal of the Association of European Psychiatrists · 2024Observational
- Outcomes of Bariatric Surgery in Patients with Schizophrenia.Nutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia often exhibits characteristics like cognitive deficits, and individuals with the condition are at a higher risk of developing metabolic syndrome. The effect of metabolic syndrome on schizophrenia-related cognitive impairment is still unknown, though. This systematic review aims to investigate the association between metabolic syndrome and cognitive impairment in patients with schizophrenia, specifically focusing on neurocognitive and social cognitive performance. Schizophrenia significantly strains the public healthcare system since it necessitates tremendous resources and care to support those suffering from the condition. Furthermore, patients with schizophrenia are more susceptible to developing obesity than the general population, leading to a higher possibility of developing metabolic syndrome. The gut microbiota has been recognized as a critical regulator of bidirectional interactions between the central nervous system and the gastrointestinal tract. Emerging evidence suggests that dysbiosis of the gut microbiota is closely linked to the development of both schizophrenia and obesity, sharing common pathophysiological mechanisms, particularly immune inflammation. In this systematic review, we examine the existing literature to explore the relationship between metabolic syndrome and cognitive impairment in individuals with schizophrenia. By synthesizing available evidence on neurocognitive and social cognitive performance, we aim to provide a comprehensive understanding of the association between metabolic syndrome and cognitive deficits in schizophrenia. The findings from this review will contribute to our knowledge of the complex interplay between metabolic abnormalities, gut microbiota dysbiosis, and cognitive impairments in patients with schizophrenia. This understanding may facilitate the development of novel interventions targeting metabolic syndrome as a potential avenue for improving cognitive outcomes in individuals with schizophrenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.